Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MDX-2001-101 study protocol: a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors.

Future oncology (London, England)·2026
Same author

Ligase-mediated programmable genomic integration (L-PGI).

Nature communications·2025
Same author

Cell and gene therapy approvals in Asia: regulatory landscape, access and affordability.

Cytotherapy·2025
Same author

Building a potent TREM2 agonistic, biparatopic, common light chain antibody.

mAbs·2025
Same author

Development of circular AAV cargos for targeted seamless insertion with large serine integrases.

Molecular therapy. Methods & clinical development·2025
Same author

Hydrogen/Deuterium Exchange and Protein Oxidative Footprinting with Mass Spectrometry Collectively Discriminate the Binding of Small-Molecule Therapeutics to Bcl-2.

Analytical chemistry·2025
Same journal

Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

Neonatal systemic gene therapy restores cardiorespiratory function in a rat model of Pompe disease.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

Endothelial injury with capillary leak: A final common pathway in acute AAV toxicity?

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

Long-term functional synaptic integration of genome-edited retinal organoids in a primate model of macular degeneration.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

Nox1/4 inhibitor Setanaxib treatment ameliorates cardiac function in mouse models of Duchenne Muscular Dystrophy.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

HSP90α-USP7-DNMT1 Axis Drives Hepatocellular Carcinoma Recurrence After Microwave Ablation by Disrupting ACSS3-Mediated Propionate Metabolism.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
See all related articles

Related Experiment Video

Updated: Nov 20, 2025

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics
08:50

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

Published on: August 16, 2024

1.1K

A versatile platform for generating engineered extracellular vesicles with defined therapeutic properties.

Kevin Dooley1, Russell E McConnell1, Ke Xu1

  • 1Codiak BioSciences, Cambridge, MA 02140, USA.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|January 23, 2021
PubMed
Summary
This summary is machine-generated.

Researchers engineered extracellular vesicles (EVs) using PTGFRN and BASP1 scaffold proteins. These modified EVs efficiently display diverse molecules on their surface and inside, showing potent therapeutic activity in preclinical models.

Keywords:
BASP1EV engineeringIL-12PTGFRNexosome engineeringexosomesextracellular vesiclessacffoldvaccine

More Related Videos

Isolation, Characterization, and Therapeutic Application of Extracellular Vesicles from Cultured Human Mesenchymal Stem Cells
07:03

Isolation, Characterization, and Therapeutic Application of Extracellular Vesicles from Cultured Human Mesenchymal Stem Cells

Published on: September 23, 2022

2.3K
A Convenient and General Expression Platform for the Production of Secreted Proteins from Human Cells
07:09

A Convenient and General Expression Platform for the Production of Secreted Proteins from Human Cells

Published on: July 31, 2012

21.6K

Related Experiment Videos

Last Updated: Nov 20, 2025

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics
08:50

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

Published on: August 16, 2024

1.1K
Isolation, Characterization, and Therapeutic Application of Extracellular Vesicles from Cultured Human Mesenchymal Stem Cells
07:03

Isolation, Characterization, and Therapeutic Application of Extracellular Vesicles from Cultured Human Mesenchymal Stem Cells

Published on: September 23, 2022

2.3K
A Convenient and General Expression Platform for the Production of Secreted Proteins from Human Cells
07:09

A Convenient and General Expression Platform for the Production of Secreted Proteins from Human Cells

Published on: July 31, 2012

21.6K

Area of Science:

  • Biotechnology
  • Cell Biology
  • Nanomedicine

Background:

  • Extracellular vesicles (EVs) are crucial for intercellular communication, mediating macromolecule transfer.
  • Therapeutic applications of EVs often require engineered systems for targeted cargo delivery.
  • Current methods for EV functionalization face challenges in achieving high-density display and diverse cargo loading.

Purpose of the Study:

  • To identify and characterize novel scaffold proteins for enhanced EV engineering.
  • To develop a versatile platform for high-density surface and luminal loading of diverse macromolecules onto EVs.
  • To evaluate the therapeutic potential and in vivo efficacy of engineered EVs.

Main Methods:

  • Identification of PTGFRN and BASP1 as EV-preferential scaffold proteins.
  • Fusion of various macromolecules (cytokines, antibody fragments, Cas9, antigens) to PTGFRN/BASP1 for EV loading.
  • Assessment of molecule loading density and in vitro bioactivity.
  • Evaluation of pharmacodynamic activity of engineered EVs in animal models.

Main Results:

  • PTGFRN and BASP1 enable high-density surface and luminal display of diverse molecules on EVs.
  • Engineered EVs demonstrated potent in vitro activity of loaded macromolecules.
  • Functionalized EVs retained significant pharmacodynamic effects in various preclinical animal models.
  • The platform supports topologically diverse macromolecule functionalization.

Conclusions:

  • PTGFRN and BASP1 serve as effective scaffold proteins for engineering therapeutic EVs.
  • This platform offers a simplified approach for creating functionalized EVs with enhanced cargo capacity.
  • Engineered EVs show significant promise for advancing EV-based therapeutics.